Pristiq (Major Depressive Disorder) Market Future Growth, Opportunities and Forecast to 2023

Pristiq (Major Depressive Disorder) Market Size, Share, Trends, Company

Profiles, Demand, Insights, Analysis, Research, Report, Opportunities,

Segmentation and Forecast To 2023

Summary

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide.

The MDD market is a crowded and competitive market, with more than 30 marketed products

available for the treatment of patients with MDD. The depression market is about to enter a

dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's

Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal

antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of

seven promising late-stage pipeline products into the market during the forecast period, from

2013 to 2023.

Pristiq (desvenlafaxine) is an SNRI antidepressant that was developed by Wyeth, before Wyeth

was acquired by Pfizer. Pristiq was launched in the US and Australia in 2008, but is not available

in the 5EU and Japan. Pristiq is closely related to Effexor, and more specifically, is the major

active metabolite of Effexor. Therefore, despite being a newer SNRI antidepressant, Pristiq will

be unable to match the success of Cymbalta and Effexor. Preclinical studies have shown that

Pristiq is a potent SNRI, which is believed to cause its antidepressant effects.

For further information on this report, please visit http://www.radiantinsights.com/research/pristiq-major-depressive-disorder-forecast-andmarket-analysis-to-2023

Scope

- Overview of Major depressive disorder, including epidemiology, etiology, symptoms,

diagnosis, pathology and treatment guidelines as well as an overview on the competitive

landscape.

- Detailed information on Pristiq including product description, safety and efficacy profiles as

well as a SWOT analysis.

- Sales forecast for Pristiq for the top three countries from 2013 to 2023.

- Sales information covered for the US, Spain and...